Codexis (CODX) Signs siRNA Manufacturing Evaluation Deal, Shares Up 3.41%

Codexis, Inc. (CODX) announced an agreement on September 28, 2026, with an unnamed siRNA drug developer to evaluate its ECO Synthesis Manufacturing Platform for next-generation RNA production. Shares rose 3.41% to $1.36. Under the deal, Codexis will produce stereo-defined oligonucleotide fragments via a fully enzymatic process, which the partner will assemble into final siRNA molecules using ligation-based chemistry. The collaboration will benchmark ECO Synthesis fragments against conventional solid-phase oligonucleotide synthesis (SPOS), assessing purity, quality and ligation performance for potential clinical development. Codexis demonstrated full-length siRNA synthesis with phosphorothioate stereochemistry control via its StereoSelect capability at TIDES USA 2026. CODX has traded between $0.96 and $2.98 over the past year. CEO Alison Moore said the collaboration could demonstrate stereochemical control that may enhance product quality and therapeutic performance.